Blog

The latest thoughts from Medicines Law & Policy partners.

The new IP strategy of war-torn Ukraine should prioritise public health and national security

Russia’s full-scale assault on Ukraine continues for the third year. The Russian occupation forces have already killed tens of thousands of civilians, including children. They have...

Pharmaceutical Accountability Foundation meets AbbVie in court, looking to advance its pricing case

“The value of a human life is infinite, but unfortunately our healthcare budget is not,” said former Dutch Health Minister Bruno Bruins, quoted by...

Worldwide licensing of pandemic technologies is already current practice. The Pandemic Accord should protect...

The negotiations for a WHO pandemic accord are still in full swing this week. Talks are taking place behind closed doors, but it is...

Something is going terribly wrong with the EU Compulsory Licensing Regulation

This week the European Parliament will vote on amendments to the Commission’s proposed regulation of the European Parliament and the Council on compulsory licensing...

It is not too late to solve the know-how problem in the WHO Pandemic...

Introduction One of the most important Intellectual Property (IP) problems which the Pandemic Accord negotiators need to solve is now in danger of being completely...

Written remarks submitted to the OHCHR following the Expert Workshop on the key challenges...

This blog was submitted by Dr. Katrina Perehudoff, Law Centre for Health and Rights at the University of Amsterdam, and Medicines Law & Policy,...

Medicines Law & Policy Intervention at the WHO Pandemic Accord Negotiations

This statement was delivered on 19 February at the World Health Organization in Geneva, on the occasion of the 8th Intergovernmental Negotiating Body to...

Commission report on competition enforcement in the pharmaceutical sector

Guest author Jacquelyn D. Veraldi is Assistant Professor of European Law at the University of Groningen. Guest author Tais A. Ruiz Palacios is a...

Fair Medicines Pricing requires addressing monopolies and increasing transparency in pharmaceutical markets

The 4th WHO Fair Pricing Forum took place from 6 - 8 February 2024. Ellen 't Hoen spoke at the opening plenary. Below are...

Medicines Law & Policy responds to US Health and Human Services Department request for...

On 12 December 2023 the US Health and Human Services Department (HHS) posted a notice and request for comments on “the implications of access...